Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First human trial of Buprenorphine depot injection for the maintenance treatment of opioid dependence and chronic pain

Next Previous
Trial Profile

First human trial of Buprenorphine depot injection for the maintenance treatment of opioid dependence and chronic pain

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Pain
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 15 May 2017 According to BioDelivery Sciences media release, results from the first dosing cohort expected to be available in the fourth quarter
    • 17 Mar 2017 Results from the first dosing cohort are expected to be available in the third quarter of 2017, according to a BioDelivery Sciences media release.
    • 09 Nov 2016 According to BioDelivery Sciences media release, the company expects to submit the IND application before the end of 2016 and expects to initiate the trial in the first quarter of 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top